Investment and M&A transaction comps
Supplement Brand Investment & M&A Transaction Comps
Supplements, vitamins, sports nutrition, wellness and functional nutrition brand transactions.
20
Reviewed transactions
12
With price data
3.7x
Median EV or valuation / revenue
16.8x
Median EV or valuation / EBITDA
| Year | Transactions | Priced | Median EV or valuation / revenue | Median EV or valuation / EBITDA |
|---|---|---|---|---|
| 2026 | 3 | 3 | 5.8x | - |
Sortable transaction comps
Supplements transaction table
Rows with reported value
13 / 20
Acquisition EV, USD
USD 21B
Investment EV, USD
-
Median EV / revenue
3.6x
Select up to 12 rows across filters and pages, then share or export the set.
Selected comparison set
Saved in this browser only. Nothing is written to FundComb data.
Choose transactions from the table to build a quick comparison set.
20 shown of 20 matching transactions. Click any transaction row for more detail.
Values are 100% enterprise values. Multiples divide EV by full-company revenue or EBITDA. Reported prices are assumed to be EV; explicit partial-stake prices are grossed up as estimates. Amounts paid are tracked separately.
| Select for comparison | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Thorne Control | 2026-08-04 | Procter & Gamble | USD 3.8B Consideration | 3,800 | 7.6x | - | United States | Estimated 3 sources | ||
| Vitabiotics Control | 2026-07-24 | Bain Capital | USD 1.0B Estimated Enterprise Value | 1,038 | - | - | United Kingdom | Confirmed 3 sources | ||
| Grüns Control (80%) | 2026-04-09 | Unilever | USD 1.2B Enterprise Value | 1,200 | 4.0x | - | United States | Estimated 3 sources | ||
| Huel Control (100%) | 2026-03-23 | Danone | EUR 1.0B Enterprise Value | 1,160 | 3.5x | 34.8x | United Kingdom | Estimated 3 sources | ||
| Sunday Natural Control (55%) | 2024-01-15 | CVC Capital Partners | EUR 800M Enterprise Value | 875 | 8.0x | 16.0x | Germany | Estimated 1 source | ||
| Thorne HealthTech Control | 2023-08-28 | L Catterton | USD 681M Enterprise Value | 681 | 3.7x | 21.2x | - | Estimated 2 sources | ||
| Blackmores Control (100%) | 2023-04-26 | Kirin | USD 1.2B Enterprise Value | 1,241 | 2.9x | 23.1x | Australia | Estimated 3 sources | ||
| The Better Health Company Control | 2022-06-29 | Nestle | Undisclosed Undisclosed | Undisclosed | - | - | New Zealand | Estimated 2 sources | ||
| 2021-04-30 | Nestlé | USD 5.8B Consideration | 5,750 | 3.1x | 16.8x | - | Confirmed 1 source | |||
| Smarty Pants Control | 2020-11-25 | Unilever | Undisclosed | Undisclosed | 4.0x | - | - | Confirmed 1 source | ||
| Care/of Control | 2020-08-31 | Bayer | USD 225M | 225 | - | - | United States | Confirmed 1 source | ||
| Nutranext Control | 2018-03-12 | Clorox | USD 700M Consideration | 700 | 3.5x | 14.0x | - | Estimated 1 source | ||
| Atrium Innovations Control | 2017-12-05 | Nestlé | USD 2.3B Consideration | 2,300 | 3.3x | 19.0x | - | Confirmed 1 source | ||
| Vitaco Control | 2016-08-01 | Primavera Capital | Undisclosed | Undisclosed | 1.5x | 14.7x | Australia/New Zealand | Confirmed 1 source | ||
| Swisse Control (83%) | 2015-09-17 | Biostime | AUD 1.7B Enterprise Value | 1,197 | 3.6x | 10.2x | Australia | Confirmed 2 sources | ||
| Schiff Nutrition Control | 2012-11-22 | Reckitt Benckiser | Undisclosed | Undisclosed | 4.2x | 19.1x | - | Confirmed 1 source | ||
| Specnova Control | - | HTBA | Undisclosed | Undisclosed | - | - | United States | Confirmed 2 sources | ||
| Twinlab Brands Control | - | cbdMD | Undisclosed | Undisclosed | - | - | - | Confirmed 2 sources | ||
| Nestlé Holistic Health Platform Control | - | Yellow Wood Partners | USD 1.0B Consideration | 1,000 | - | - | - | Confirmed 2 sources | ||
| Twinlab Control | - | cbdMD | Undisclosed Consideration | Undisclosed | - | - | - | Confirmed 2 sources |
FundComb transaction comps are informational only. Prices are shown as estimated enterprise value where available, with USD used as the default sorting currency; revenue and EBITDA multiples are shown where available. Values may be estimated, rumored, incomplete or derived from public information and should not be relied upon as financial, investment or valuation advice.